4//SEC Filing
Dahan Michel 4
Accession 0001562180-23-002198
CIK 0001517022other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 8:01 AM ET
Size
8.6 KB
Accession
0001562180-23-002198
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2023-03-01$0.88/sh−10,476$9,193→ 271,393 total - Sale
Common Stock
2023-03-01$0.88/sh−1,878$1,648→ 269,515 total - Sale
Common Stock
2023-03-01$0.88/sh−8,058$7,071→ 281,869 total
Footnotes (3)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.
- [F2]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
- [F3]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
Documents
Issuer
Akebia Therapeutics, Inc.
CIK 0001517022
Entity typeother
Related Parties
1- filerCIK 0001669737
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 8:01 AM ET
- Size
- 8.6 KB